EA8212 / BRIDGE — Intravesical BCG versus gemcitabine–docetaxel in high-grade non-muscle-invasive bladder cancer

Phase 3 · Bladder Cancer

Population

BCG-naive high-grade non-muscle-invasive bladder cancer.

Primary Endpoint

Event-free survival

Rationale

Intravesical BCG is standard for high-grade non-muscle-invasive bladder cancer but is frequently in short supply. BRIDGE tests whether intravesical gemcitabine plus docetaxel is as effective, offering a reliable alternative.

What It Could Change

Could validate a chemotherapy alternative to scarce BCG for early bladder cancer.